A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 500 participants.

Also called NCT06481891

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06481891
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Belgium, Brazil, Bulgaria, Croatia, Czechia, France, Georgia, Germany, Hungary, Israel, Italy, Poland, Portugal, Romania, Serbia, Sweden, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06481891. Randomized; quadruple masking; primary purpose treatment. Start 2024-09-24 (actual); primary completion 2027-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Acronym
SONATA-HCM
Condition
Obstructive Cardiomyopathy, Hypertrophic
Condition
Non-obstructive Hypertrophic Cardiomyopathy
Intervention (Drug)
Sotagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Lexicon Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06481891
Content hash
d493256891ec6be3b24827fc80c2646989ed78a62faf207ddcc2d0d81799b545